These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 32039516)

  • 1. Absence of microglia or presence of peripherally-derived macrophages does not affect tau pathology in young or old hTau mice.
    Zhu K; Pieber M; Han J; Blomgren K; Zhang XM; Harris RA; Lund H
    Glia; 2020 Jul; 68(7):1466-1478. PubMed ID: 32039516
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genetically enhancing the expression of chemokine domain of CX
    Bemiller SM; Maphis NM; Formica SV; Wilson GN; Miller CM; Xu G; Kokiko-Cochran ON; Kim KW; Jung S; Cannon JL; Crish SD; Cardona AE; Lamb BT; Bhaskar K
    J Neuroinflammation; 2018 Sep; 15(1):278. PubMed ID: 30253780
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Traumatic Brain Injury in hTau Model Mice: Enhanced Acute Macrophage Response and Altered Long-Term Recovery.
    Kokiko-Cochran ON; Saber M; Puntambekar S; Bemiller SM; Katsumoto A; Lee YS; Bhaskar K; Ransohoff RM; Lamb BT
    J Neurotrauma; 2018 Jan; 35(1):73-84. PubMed ID: 28859549
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reactive microglia drive tau pathology and contribute to the spreading of pathological tau in the brain.
    Maphis N; Xu G; Kokiko-Cochran ON; Jiang S; Cardona A; Ransohoff RM; Lamb BT; Bhaskar K
    Brain; 2015 Jun; 138(Pt 6):1738-55. PubMed ID: 25833819
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Microglial activation arises after aggregation of phosphorylated-tau in a neuron-specific P301S tauopathy mouse model.
    van Olst L; Verhaege D; Franssen M; Kamermans A; Roucourt B; Carmans S; Ytebrouck E; van der Pol SMA; Wever D; Popovic M; Vandenbroucke RE; Sobrino T; Schouten M; de Vries HE
    Neurobiol Aging; 2020 May; 89():89-98. PubMed ID: 32008854
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of CX3CR1 and Fractalkine Chemokines in Amyloid Beta Clearance and p-Tau Accumulation in Alzheimer's Disease (AD) Rodent Models: Is Fractalkine a Systemic Biomarker for AD?
    Merino JJ; Muñetón-Gómez V; Alvárez MI; Toledano-Díaz A
    Curr Alzheimer Res; 2016; 13(4):403-12. PubMed ID: 26567742
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Specific targeting of tau oligomers in Htau mice prevents cognitive impairment and tau toxicity following injection with brain-derived tau oligomeric seeds.
    Castillo-Carranza DL; Gerson JE; Sengupta U; Guerrero-Muñoz MJ; Lasagna-Reeves CA; Kayed R
    J Alzheimers Dis; 2014; 40 Suppl 1():S97-S111. PubMed ID: 24603946
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Peripherally derived angiotensin converting enzyme-enhanced macrophages alleviate Alzheimer-related disease.
    Koronyo-Hamaoui M; Sheyn J; Hayden EY; Li S; Fuchs DT; Regis GC; Lopes DHJ; Black KL; Bernstein KE; Teplow DB; Fuchs S; Koronyo Y; Rentsendorj A
    Brain; 2020 Jan; 143(1):336-358. PubMed ID: 31794021
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selective suppression of the α isoform of p38 MAPK rescues late-stage tau pathology.
    Maphis N; Jiang S; Xu G; Kokiko-Cochran ON; Roy SM; Van Eldik LJ; Watterson DM; Lamb BT; Bhaskar K
    Alzheimers Res Ther; 2016 Dec; 8(1):54. PubMed ID: 27974048
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early depletion of CA1 neurons and late neurodegeneration in a mouse tauopathy model.
    Helboe L; Egebjerg J; Barkholt P; Volbracht C
    Brain Res; 2017 Jun; 1665():22-35. PubMed ID: 28411086
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Microglia display modest phagocytic capacity for extracellular tau oligomers.
    Majerova P; Zilkova M; Kazmerova Z; Kovac A; Paholikova K; Kovacech B; Zilka N; Novak M
    J Neuroinflammation; 2014 Sep; 11():161. PubMed ID: 25217135
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Aggregated Tau activates NLRP3-ASC inflammasome exacerbating exogenously seeded and non-exogenously seeded Tau pathology in vivo.
    Stancu IC; Cremers N; Vanrusselt H; Couturier J; Vanoosthuyse A; Kessels S; Lodder C; Brône B; Huaux F; Octave JN; Terwel D; Dewachter I
    Acta Neuropathol; 2019 Apr; 137(4):599-617. PubMed ID: 30721409
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Microglia in Alzheimer's Disease in the Context of Tau Pathology.
    Perea JR; Bolós M; Avila J
    Biomolecules; 2020 Oct; 10(10):. PubMed ID: 33066368
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel transgenic mouse expressing double mutant tau driven by its natural promoter exhibits tauopathy characteristics.
    Rosenmann H; Grigoriadis N; Eldar-Levy H; Avital A; Rozenstein L; Touloumi O; Behar L; Ben-Hur T; Avraham Y; Berry E; Segal M; Ginzburg I; Abramsky O
    Exp Neurol; 2008 Jul; 212(1):71-84. PubMed ID: 18490011
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Partial reduction of microglia does not affect tau pathology in aged mice.
    Bennett RE; Bryant A; Hu M; Robbins AB; Hopp SC; Hyman BT
    J Neuroinflammation; 2018 Nov; 15(1):311. PubMed ID: 30413160
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Insulin deprivation induces PP2A inhibition and tau hyperphosphorylation in hTau mice, a model of Alzheimer's disease-like tau pathology.
    Gratuze M; Julien J; Petry FR; Morin F; Planel E
    Sci Rep; 2017 Apr; 7():46359. PubMed ID: 28402338
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Microglial activation in brain lesions with tau deposits: comparison of human tauopathies and tau transgenic mice TgTauP301L.
    Sasaki A; Kawarabayashi T; Murakami T; Matsubara E; Ikeda M; Hagiwara H; Westaway D; George-Hyslop PS; Shoji M; Nakazato Y
    Brain Res; 2008 Jun; 1214():159-68. PubMed ID: 18457819
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Age-dependent effects of microglial inhibition in vivo on Alzheimer's disease neuropathology using bioactive-conjugated iron oxide nanoparticles.
    Glat M; Skaat H; Menkes-Caspi N; Margel S; Stern EA
    J Nanobiotechnology; 2013 Sep; 11():32. PubMed ID: 24059692
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased tauopathy drives microglia-mediated clearance of beta-amyloid.
    Chen W; Abud EA; Yeung ST; Lakatos A; Nassi T; Wang J; Blum D; Buée L; Poon WW; Blurton-Jones M
    Acta Neuropathol Commun; 2016 Jun; 4(1):63. PubMed ID: 27339073
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TREM2 modifies microglial phenotype and provides neuroprotection in P301S tau transgenic mice.
    Jiang T; Zhang YD; Chen Q; Gao Q; Zhu XC; Zhou JS; Shi JQ; Lu H; Tan L; Yu JT
    Neuropharmacology; 2016 Jun; 105():196-206. PubMed ID: 26802771
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.